PDF(Pubmed)
Abstract：
UNASSIGNED: Given the uncertainties related to IV iron therapy and the potential risk of infection, health care providers may hesitate to use this preparation to treat hospitalized patients with bacterial infections, even if clinically indicated. The aim of this study was to examine patterns of prescribing IV iron in patients who were hospitalized and treated for a bacterial infection, and their associated clinical outcomes.
UNASSIGNED: This retrospective chart review evaluated adult patients who received both IV iron sucrose and antibiotics during the same admission at Maine Medical Center in 2019. Data collected included iron studies, practices for prescribing IV iron, and clinical outcomes. Data were summarized using descriptive statistics.
UNASSIGNED: A total of 197 patients were evaluated. The median duration of antibiotic therapy was 5(4-9) days. Iron and antibiotic administration overlapped in 153(77.7%) patients, with a mean overlap of 2.7(1-7) days. In the 44 patients without overlap, 20(46%) received IV iron before antibiotics. More than half (57%) of infection types involved urinary tract and respiratory systems. Approximately 2% of patients had antibiotic therapy broadened or duration extended, 7% died, and 16% were readmitted within 30 days of discharge.
UNASSIGNED: Prior studies evaluating the risk of infection with IV iron published conflicting results. This is the only study that analyzed outcomes in patients receiving IV iron and antibiotics for infection but not undergoing hemodialysis during a hospital admission. Although our findings support that IV iron treatment is safe among patients with concomitant infection and iron deficiency, this finding may not be the case for all clinical subgroups.
UNASSIGNED: This study showed that when patients were administered IV iron in the setting of acute bacterial infection in our facility, most patients did not have negative outcomes.
UNASSIGNED: This retrospective chart review evaluated adult patients who received both IV iron sucrose and antibiotics during the same admission at Maine Medical Center in 2019. Data collected included iron studies, practices for prescribing IV iron, and clinical outcomes. Data were summarized using descriptive statistics.
UNASSIGNED: A total of 197 patients were evaluated. The median duration of antibiotic therapy was 5(4-9) days. Iron and antibiotic administration overlapped in 153(77.7%) patients, with a mean overlap of 2.7(1-7) days. In the 44 patients without overlap, 20(46%) received IV iron before antibiotics. More than half (57%) of infection types involved urinary tract and respiratory systems. Approximately 2% of patients had antibiotic therapy broadened or duration extended, 7% died, and 16% were readmitted within 30 days of discharge.
UNASSIGNED: Prior studies evaluating the risk of infection with IV iron published conflicting results. This is the only study that analyzed outcomes in patients receiving IV iron and antibiotics for infection but not undergoing hemodialysis during a hospital admission. Although our findings support that IV iron treatment is safe among patients with concomitant infection and iron deficiency, this finding may not be the case for all clinical subgroups.
UNASSIGNED: This study showed that when patients were administered IV iron in the setting of acute bacterial infection in our facility, most patients did not have negative outcomes.
摘要：
■考虑到与静脉铁治疗相关的不确定性和潜在的感染风险，卫生保健提供者可能会犹豫使用这种制剂来治疗细菌感染的住院患者，即使有临床指征。这项研究的目的是检查住院并接受细菌感染治疗的患者的静脉铁处方模式，及其相关的临床结果。
■这项回顾性图表评估了2019年在缅因州医学中心同一入院期间同时接受IV蔗糖铁和抗生素的成年患者。收集的数据包括铁研究，开IV铁的做法，和临床结果。使用描述性统计对数据进行汇总。
■共评估了197例患者。抗生素治疗的中位持续时间为5(4-9)天。153例（77.7%）患者的铁和抗生素给药重叠，平均重叠2.7（1-7）天。在44名没有重叠的患者中，20例(46%)在抗生素前接收静脉补铁。超过一半（57％）的感染类型涉及泌尿道和呼吸系统。大约2%的患者抗生素治疗扩大或持续时间延长，7%死亡,16％在出院后30天内再次入院。
■先前评估静脉铁感染风险的研究发表了相互矛盾的结果。这是唯一一项分析接受静脉铁剂和抗生素治疗感染但在住院期间未接受血液透析的患者结局的研究。虽然我们的研究结果支持静脉铁治疗在合并感染和铁缺乏的患者中是安全的，这一发现可能并非适用于所有临床亚组.
■这项研究表明，在我们的设施中，当患者在急性细菌感染的情况下接受静脉铁时，大多数患者没有阴性结局.
■这项回顾性图表评估了2019年在缅因州医学中心同一入院期间同时接受IV蔗糖铁和抗生素的成年患者。收集的数据包括铁研究，开IV铁的做法，和临床结果。使用描述性统计对数据进行汇总。
■共评估了197例患者。抗生素治疗的中位持续时间为5(4-9)天。153例（77.7%）患者的铁和抗生素给药重叠，平均重叠2.7（1-7）天。在44名没有重叠的患者中，20例(46%)在抗生素前接收静脉补铁。超过一半（57％）的感染类型涉及泌尿道和呼吸系统。大约2%的患者抗生素治疗扩大或持续时间延长，7%死亡,16％在出院后30天内再次入院。
■先前评估静脉铁感染风险的研究发表了相互矛盾的结果。这是唯一一项分析接受静脉铁剂和抗生素治疗感染但在住院期间未接受血液透析的患者结局的研究。虽然我们的研究结果支持静脉铁治疗在合并感染和铁缺乏的患者中是安全的，这一发现可能并非适用于所有临床亚组.
■这项研究表明，在我们的设施中，当患者在急性细菌感染的情况下接受静脉铁时，大多数患者没有阴性结局.
